Welcome To Our Website!SALES DEPT:info@puresynmr.com

ProductsHome>Products

SARMS/LIGANDROL/LGD4033-selective androgen receptor modulator

CAS#: 1165910-22-4

Product Price: Contact us to get the latest price

Product Specification : 98%

Minmum Order Quantity : >50g

Sample Requirement : Free Sample / Freight Charged / to final agreement

Product No.: PURLGDROL

Product Introduction

What is LIGANDROL(LGD-4033)?

LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

How it works?

LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers.

Dosages and Suggestion

Recommended maximum dose LIGANDROL the safety and tolerability up to doses of 22 mg -25mg . It has a half-life of 24 hours a day.

SARMS We offer

AICAR

2627-69-2

acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown

MK2866

841205-47-8

medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.

MK-677

15972-10-0

A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly

LGD-4033

1165910-22-4

pharmacological profile similar to that of enobosarm, Ostarine,MK-2866

GW1516

317318-70-0

For obesity, diabetes, dyslipidemia and cardiovascular disease

Andarine(S4)

401900-40-0

partial agonist, intended mainly for treatment of benign prostatic hypertrophy

SR9009

1379686-30-2

under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice

SR9011

1379686-30-2

For obesity, diabetes, dyslipidemia and cardiovascular disease

RAD140

1182367-47-0

New generation for gaining mass and cutting edges

YK11

366508-78-3

431579-34-9

a SARM and myostatin inhibitor in one

GHRP-2

158861-67-7

Growth Hormone Releasing Peptide-2

GHRP-6

87616-84-0

Growth Hormone Releasing Peptide-6

TB500

107761-42-2

Thymosin beta 4

SM130,686

/

/

Copyright © 2012 SYNMR All Rights Reserved. Design by Baiqi